| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $94,018 | 2 | 15 |
Sells | $108,846 | 11 | 85 |
| Irrevocable Larson Family Investment Trust | 10 percent owner | 2 | $94,018 | 0 | $0 | $94,018 |
| Neri Jesse | SVP, FINANCE AND CFO | 0 | $0 | 2 | $1,701 | $-1,701 |
| Chole Timothy | SVP, Chief Commercial Officer | 0 | $0 | 4 | $11,190 | $-11,190 |
| Strobeck Mark | President and CEO | 0 | $0 | 4 | $25,575 | $-25,575 |
| RAVICH MARK H | director | 0 | $0 | 1 | $70,379 | $-70,379 |
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Over the last 12 months, insiders at Rockwell Medical, Inc. have bought $94,018 and sold $108,846 worth of Rockwell Medical, Inc. stock.
On average, over the past 5 years, insiders at Rockwell Medical, Inc. have bought $94,018 and sold $494,862 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Irrevocable Larson Family Investment Trust (10 percent owner) — $94,018.
The last purchase of 30,500 shares for transaction amount of $32,982 was made by Irrevocable Larson Family Investment Trust (10 percent owner) on 2025‑04‑11.
| 2025-07-01 | Sale | Strobeck Mark | President and CEO | 6,926 0.02% | $0.82 | $5,679 | +30.52% | |
| 2025-07-01 | Sale | Chole Timothy | SVP and CCO | 2,868 0.0083% | $0.82 | $2,352 | +30.52% | |
| 2025-07-01 | Sale | Neri Jesse | SVP and CFO | 886 0.0026% | $0.82 | $727 | +30.52% | |
| 2025-04-11 | Irrevocable Larson Family Investment Trust | 10 percent owner | 30,500 0.0997% | $1.08 | $32,982 | -4.25% | ||
| 2025-04-10 | Irrevocable Larson Family Investment Trust | 10 percent owner | 57,000 0.1846% | $1.07 | $61,036 | -4.67% | ||
| 2025-04-01 | Sale | Strobeck Mark | President and CEO | 6,926 0.0203% | $1.08 | $7,480 | -5.56% | |
| 2025-04-01 | Sale | Chole Timothy | SVP, Chief Commercial Officer | 2,868 0.0084% | $1.08 | $3,097 | -5.56% | |
| 2025-04-01 | Sale | Neri Jesse | SVP, FINANCE AND CFO | 886 0.0026% | $1.10 | $975 | -5.56% | |
| 2025-01-02 | Sale | Strobeck Mark | President and CEO | 2,163 0.0062% | $2.06 | $4,445 | -48.42% | |
| 2025-01-02 | Sale | Chole Timothy | SVP, Chief Commercial Officer | 1,001 0.0029% | $2.05 | $2,052 | -48.42% | |
| 2024-11-15 | Sale | RAVICH MARK H | director | 29,991 0.0915% | $2.35 | $70,379 | -35.59% | |
| 2024-10-01 | Sale | Strobeck Mark | President and CEO | 2,163 0.0068% | $3.69 | $7,971 | -52.04% | |
| 2024-10-01 | Sale | Chole Timothy | SVP, Chief Commercial Officer | 1,001 0.0032% | $3.69 | $3,689 | -52.04% | |
| 2020-12-21 | Sale | Richmond David S. | 10 percent owner | 42,450 0.0609% | $1.03 | $43,724 | -13.00% | |
| 2020-12-16 | Sale | Richmond David S. | 10 percent owner | 521,876 0.7092% | $1.01 | $529,649 | -15.87% | |
| 2020-12-15 | Sale | Richmond David S. | 10 percent owner | 278,124 0.3947% | $1.11 | $307,505 | -19.27% | |
| 2020-06-30 | Richmond David S. | 10 percent owner | 24,681 0.034% | $1.93 | $47,563 | -43.33% | ||
| 2020-05-14 | ELLISON RUSSELL H | See Remarks | 2,000 0.003% | $2.08 | $4,160 | -38.50% | ||
| 2019-08-02 | Richmond David S. | 10 percent owner | 97 0.0002% | $2.42 | $235 | -5.31% | ||
| 2019-07-31 | Richmond David S. | 10 percent owner | 1,807 0.0028% | $2.66 | $4,806 | -12.78% |
| Irrevocable Larson Family Investment Trust | 10 percent owner | 3557500 10.4097% | $3.81M | 2 | 0 | |
| Strobeck Mark | President and CEO | 337752 0.9883% | $361,394.64 | 0 | 4 | |
| Chole Timothy | SVP and CCO | 128167 0.375% | $137,138.69 | 0 | 4 | |
| Neri Jesse | SVP and CFO | 126614 0.3705% | $135,476.98 | 0 | 2 | |
| RAVICH MARK H | director | 0 0% | $0 | 0 | 1 | |
| CHIOINI ROBERT L | Chairman, President and CEO | 1793933 5.2493% | $1.92M | 2 | 9 | <0.0001% |
| Richmond David S. | 10 percent owner | 1433309 4.1941% | $1.53M | 16 | 4 | <0.0001% |
| HAGELSTEIN DAVID A | 10 percent owner | 1360700 3.9816% | $1.46M | 34 | 4 | +6.89% |
| Paul Stuart M | Chief Executive Officer | 363798 1.0645% | $389,263.86 | 1 | 0 | <0.0001% |
| Gupta Ajay | Chief Scientific Officer | 326667 0.9559% | $349,533.69 | 1 | 0 | <0.0001% |
| KLEMA THOMAS E | Vice President, CFO | 232526 0.6804% | $248,802.82 | 0 | 1 | |
| Smith Angus W. | Chief Financial Officer | 176667 0.517% | $189,033.69 | 1 | 0 | <0.0001% |
| Richmond Brothers, Inc. | director | 161278 0.4719% | $172,567.46 | 0 | 1 | |
| Pratt Raymond Dennis | VP of Drug Development | 160700 0.4702% | $171,949.00 | 1 | 0 | <0.0001% |
| BOYD RONALD D | director | 32500 0.0951% | $34,775.00 | 0 | 13 | |
| HOLT KENNETH L | director | 12630 0.037% | $13,514.10 | 0 | 45 | |
| ELLISON RUSSELL H | See Remarks | 12050 0.0353% | $12,893.50 | 1 | 0 | <0.0001% |
$2,051,022 | 1591 | -12.84% | $58.05M | |
$22,899,264 | 81 | 34.90% | $17.46M | |
$218,350,131 | 64 | 16.68% | $221.98M | |
Rockwell Medical, Inc. (RMTI) | $125,860,243 | 57 | -4.48% | $36.57M |
$2,740,482 | 50 | 9.37% | $29.66M | |
$30,209,812 | 45 | -1.91% | $13.31M | |
$3,140,759 | 30 | 10.79% | $15.45M | |
$423,174,478 | 29 | -7.58% | $38.46M | |
$32,539,771 | 28 | 33.37% | $230.33M | |
$25,034,841 | 20 | 9.38% | $119.7M | |
$934,616 | 12 | 74.76% | $8.2M | |
$758,061 | 9 | 60.03% | $167.73M | |
$4,039,981 | 8 | -3.44% | $13.18M | |
$179,515 | 7 | 1.51% | $379.4M | |
$8,171,353 | 7 | -14.29% | $14.31M | |
$138,873 | 5 | 1.23% | $65.14M | |
$15,894 | 5 | -31.45% | $8.82M | |
$5,003,136 | 1 | -14.58% | $284.35M | |
$999,999 | 1 | -52.42% | $14.43M |
| Increased Positions | 14 | +20% | 258,683 | +3.14% |
| Decreased Positions | 27 | -38.57% | 2M | -18.19% |
| New Positions | 4 | New | 79,940 | New |
| Sold Out Positions | 8 | Sold Out | 176,970 | Sold Out |
| Total Postitions | 57 | -18.57% | 7M | -15.05% |
| Armistice Capital, Llc | $3,744.00 | 8.95% | 3.04M | -537,847 | -15.02% | 2024-12-31 |
| Vanguard Group Inc | $1,481.00 | 3.54% | 1.2M | 0 | 0% | 2024-12-31 |
| Globeflex Capital L P | $914.00 | 2.19% | 743,256 | 0 | 0% | 2024-12-31 |
| Marshall Wace, Llp | $734.00 | 1.75% | 596,359 | +87,685 | +17.24% | 2024-12-31 |
| Renaissance Technologies Llc | $544.00 | 1.3% | 442,350 | +327,678 | +285.75% | 2024-12-31 |
| Geode Capital Management, Llc | $394.00 | 0.94% | 320,416 | +13,122 | +4.27% | 2024-12-31 |
| Ameriprise Financial Inc | $273.00 | 0.65% | 221,955 | -388 | -0.17% | 2024-12-31 |
| Blackrock, Inc. | $273.00 | 0.65% | 221,731 | -32,664 | -12.84% | 2025-03-31 |
| Susquehanna International Group, Llp | $178.00 | 0.43% | 144,428 | +45,354 | +45.78% | 2024-12-31 |
| Arrowstreet Capital, Limited Partnership | $131.00 | 0.31% | 106,135 | -38,466 | -26.6% | 2024-12-31 |